Ovagen

Source-reported examples · not treatment recommendations

Amount

10–150 micrograms per day

Frequency

Once daily

Cycle / observation period

16 weeks

Route / research model

Subcutaneous

At the source concentration, its smallest amounts would require volumes below ordinary syringe graduations. No syringe draw instructions are supplied here.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• A 2014 renal-culture study identified EDL as T-35 and associated its effect with MMP-14, while assigning cell-renewal activity to T-31/AED and a kidney polypeptide complex. Another report described EDL- and AED-associated changes in proliferation and aging-marker expression in renal cultures. These observations should remain sequence-specific. ^{[1] [2]}
• A 2015 study tested EDL and other preparations in rats with cisplatin-induced acute renal failure. The abstract reported improvements in multiple renal-function measures with EDL, including filtration and urinary measures. This is animal functional evidence, a different level from isolated-cell signaling, but it is not a clinical kidney-treatment trial. ^[3]
• A 2018 report compared a kidney polypeptide complex and AED, EDL and AEDG in old rats. It described differing renal responses across the preparations, including increased urine output with EDL and changes in sodium handling. The result should not be summarized as every peptide improving every kidney measurement. ^[4]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 9 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. T-35 study
2. renal aging-marker study
3. Original cisplatin study
4. Original aging-rat study
5. MDPI International Journal of Molecular SciencesFurther reading · Listed in reference bibliography.
6. Nature — Signal Transduction and Targeted TherapyFurther reading · Listed in reference bibliography.
7. PubMed — BiochemistryFurther reading · Listed in reference bibliography.
8. PubMed — BiochemistryFurther reading · Listed in reference bibliography.
9. NCBI Bookshelf — WHOFurther reading · Listed in reference bibliography.
10. CDCGeneral guidance · Listed in reference bibliography.
11. CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.